{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '9.5', 'Subgroup Analysis', 'All subgroup analyses will be exploratory (post hoc) in nature. The details of these analyses', 'will be described in the SAP and provided prior to the database lock. No specific subgroup', 'analysis will be described in detail in the protocol.', '9.6', 'Safety Monitoring Committees', 'A DSMB and CVAC will oversee the study from a safety and CV monitoring perspective, as', 'described in Section 7.4.4.', '9.7', 'Interim Analysis', 'For any interim data cuts or analyses which occur, the details will be specified in the SAP.', 'Amendment 2: 06 March 2019', '135', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '10.', 'ETHICS', '10.1 Institutional Review Board/Independent Ethics Committee', 'An IRB/IEC should approve the final protocol, including the final version of the ICFs and', 'any other written information and/or materials to be provided to the subjects. The', \"Investigator will provide R-Pharm International or R-Pharm International's designee with\", 'documentation of IRB/IEC approval of the protocol and the ICFs before the study may begin', 'at the study site(s). The Investigator should submit the written approval to R-Pharm', 'International or its designee before enrollment of any subject into the study.', 'R-Pharm International or its designee should approve any modifications to the ICF that are', 'needed to meet local requirements.', 'The Investigator will supply documentation to R-Pharm International or R-Pharm', \"International's designee of required IRB/IEC's annual renewal of the protocol, and any\", 'approvals of revisions to the ICF or amendments to the protocol.', 'The Investigator will report promptly to the IRB/IEC, any new information that may', 'adversely affect the safety of subjects or the conduct of the study. Similarly, the Investigator', 'will submit written summaries of the study status to the IRB/IEC annually, or more', 'frequently if requested by the IRB/IEC. Upon completion of the study, the Investigator will', 'provide the ethics committee with a brief report of the outcome of the study, if required.', 'R-Pharm International or its designee will handle the distribution of any of these documents', 'to the national regulatory authorities.', 'R-Pharm International or its designee will provide Regulatory Authorities, IRBs/IECs, and', 'Investigators with safety updates/reports according to local requirements, including SUSARs,', 'where relevant.', 'Each Investigator is responsible for providing the IRB/IEC with reports of any serious and', 'unexpected adverse drug reactions from any other study conducted with the study treatment.', 'R-Pharm International or its designee will provide this information to the Investigator so that', 'he/she can meet these reporting requirements.', '10.2 Ethical Conduct of the Study', 'The GCP is an international ethical and scientific quality standard for designing, conducting,', 'recording, and reporting studies that involve the participation of human subjects. The study', 'will be conducted in compliance with GCP and the applicable national regulations so as to', 'Amendment 2: 06 March 2019', '136', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'assure that the rights, safety, and well-being of the participating study subjects are protected', 'consistent with the ethical principles that have their origin in the Declaration of Helsinki.', '10.3 Subject Information and Informed Consent', 'The ICFs (i.e., ICF for subjects and a separate ICF for caregivers [if applicable]) will be used', 'to explain the risks and benefits of study participation to the subject in simple terms before', 'the subject will be entered into the study. The ICFs contains a statement that the consent is', 'freely given, that the subject is aware of the risks and benefits of entering the study, and that', 'the subject is free to withdraw from the study at any time. Written consent must be given by', 'the subject and/or legal representative after the receipt of detailed information on the study.', 'All ICFs must be available in the local and vernacular languages required at the study site', 'and include subject information sheets/brochures that outline the study procedures. All ICFs', 'must be signed and dated by the subject or a legally acceptable representative.', 'For subjects who are unable to read and write, the subject information sheet and ICF should', 'be read to the subject in his/her native language in the presence of an impartial witness who', 'is literate and not affiliated with the study. The subject having understood the information', 'given to him/her in the presence of an impartial witness will thumbprint the ICF and the same', 'will be countersigned by the impartial witness. If the subject or legally acceptable', 'representative cannot read then an impartial witness will witness and attest the entire consent', \"process and will be required to sign the consent form. Confirmation of a subject's informed\", \"consent must also be documented in the subject's medical record prior to any testing under\", 'this protocol, including Screening tests and assessments.', 'The Investigator is responsible for ensuring that informed consent is obtained from each', 'subject or legal representative and for obtaining the appropriate signatures and dates on the', 'ICF prior to the performance of any protocol procedures and prior to the administration of', 'study treatment. The Investigator will provide each subject with a copy of the signed and', \"dated consent form while the originals will be retained in the Investigator's records.\", '10.4 Subject Data Protection', 'The ICF will incorporate or, in some cases, be accompanied by a separate document', 'incorporating wording that complies with relevant data protection and privacy legislation. R-', \"Pharm International or R-Pharm International's designee will not provide individual results\", 'to subjects, any insurance company, any employer, their family members, general physician,', 'or any other third party, unless required to do so by law.', 'Information about study subjects will be kept confidential and managed according to the', 'regulatory requirements.', 'Amendment 2: 06 March 2019', '137', 'Confidential']\n\n###\n\n", "completion": "END"}